BusinessLonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic AcidemiaBy Nasdaq OMXFeb 16, 2017, 12:01 PM UTC
BusinessLonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic AcidemiaBy Nasdaq OMXFeb 16, 2017, 12:01 PM UTC
BusinessVoyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s DiseaseBy Nasdaq OMXJan 20, 2017, 12:31 PM UTC
BusinessVoyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s DiseaseBy Nasdaq OMXDec 7, 2016, 9:05 PM UTC
BusinessSelecta Biosciences Presented Preclinical Data Applying SVP-Rapamycin in Gene Therapy at Annual Congress of the European Society of Gene and Cell TherapyBy Nasdaq OMXOct 20, 2016, 12:01 PM UTC
BusinessSelecta Biosciences Presented Preclinical Data Applying SVP-Rapamycin in Gene Therapy at Annual Congress of the European Society of Gene and Cell TherapyBy Nasdaq OMXOct 20, 2016, 12:01 PM UTC
BusinessUK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia ABy Nasdaq OMXOct 13, 2016, 8:01 PM UTC
BusinessVoyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of TechnologyBy Nasdaq OMXSep 15, 2016, 11:05 AM UTC
